文献速递炎症性肠病

干细胞治疗在炎症性肠病治疗中是否已可常规应用?

Is Stem Cell Therapy Ready for Prime Time in Treatment of Inflammatory Bowel Diseases?
PubMed 文献 · Gastroenterology · 2016-11-11

本文讨论自体造血干细胞移植(HSCT)用于难治性克罗恩病(CD)、间充质基质细胞疗法用于瘘管性CD的临床应用前景。近期试验显示这两种免疫疗法作为全身治疗和抗生素的替代方案取得有希望的结果,但作者质疑其是否已可常规应用。

要点

  • 自体HSCT适用于多种获批治疗失败、多次手术、长期疾病活动且生活质量差的CD患者。
  • 间充质基质细胞疗法局部注入瘘管,下调局部免疫反应并诱导伤口愈合。
  • 近期试验结果有希望,但作者质疑这些免疫疗法是否已可常规应用。

核心结论

  • 近期试验显示HSCT和间充质基质细胞疗法作为炎症性肠病患者的全身治疗和抗生素替代方案取得有希望的结果,但作者质疑这些免疫疗法是否已可常规应用。

研究设计与样本

  • 本文为综述,讨论自体HSCT用于难治性CD和间充质基质细胞疗法用于瘘管性CD的临床应用前景。

主要发现

  • 适合HSCT的CD患者通常已对多数获批治疗失败、接受过多次手术,并经历多年疾病活动和较差的生活质量。
  • HSCT的目的是立即关闭免疫反应,使移植的干细胞发育为自身耐受的淋巴细胞。
  • 对于瘘管性CD患者,间充质基质细胞疗法将MSCs局部沉积到瘘管中,以下调局部免疫反应并诱导伤口愈合。
  • 近期试验显示HSCT和间充质基质细胞疗法作为全身治疗和抗生素的替代方案取得有希望的结果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autologous hematopoietic stem cell transplantation (HSCT) and mesenchymal stromal cell therapy have been proposed for patients with refractory Crohn's disease (CD) and fistulizing CD, respectively. Will these highly advanced techniques be available only for select patients, at specialized centers, or is further clinical development justified, with the aim of offering widespread, more definitive therapeutic options for often very difficult to treat disease? Patients with CD who are eligible for HSCT have typically been failed by most approved therapies, have undergone multiple surgeries, and have coped with years of disease activity and poor quality of life. The objective of HSCT is to immediately shut down the immune response and allow the transplanted stem cells to develop into self-tolerant lymphocytes. For patients with fistulizing CD, mesenchymal stromal cell therapy deposits MSCs locally, into fistulizing tracts, to down-regulate the local immune response and induce wound healing. Recent trials have produced promising results for HSCT and mesenchymal stromal cell therapy as alternatives to systemic therapies and antibiotics for patients with inflammatory bowel diseases, but are these immunotherapies ready for prime time?

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Hawkey CJ, Hommes DW. Is Stem Cell Therapy Ready for Prime Time in Treatment of Inflammatory Bowel Diseases? Gastroenterology. 2016. PMID: 27845055. doi:10.1053/j.gastro.2016.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。